1-3 of 3
Ceri Bygrave, MD FRCPath, MPhil
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy and Safety of Carfilzomib at 56mg/m 2 with Cyclophosphamide and Dexamethasone (K56Cd) in Newly Diagnosed Multiple Myeloma Patients Followed By ASCT or K56Cd Consolidation: Initial Results of the Phase 2 Cardamon Study

Kwee Yong, Rakesh Popat, William Wilson, Gavin Pang, Richard Jenner, Ruth M De Tute, BSc,MSc, Karthik Ramasamy, MBBS MRCP FRCPath PhD, Matthew Streetly, MD, Jamie Cavenagh, MD PhD, Jonathan Sive, MD, Michael Chapman, PhD MRCP, FRCPath, Ceri Bygrave, MD FRCPath, MPhil, Beth Phillips, MBBS, FRCPath, BSc, Selina J Chavda, Andres E. Virchis, FRCP, FRCPath, Reuben Benjamin, FRCPath, MRCP, MBBS, PhD, Sarah Arnott, Fenella Willis, Sandra Hassan, MBBS, MRCP, FRCPath, MDRes), Sally Moore, Laura Clifton-Hadley, PhDBSc, Roger G Owen, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 861.
https://doi.org/10.1182/blood-2019-127992
Published: 2019
Journal Articles

Carfilzomib Versus Bortezomib in Combination with Cyclophosphamide and Dexamethasone for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): Outcomes Based on Genetic Risk and Long Term Follow up of the Phase 2 Muk Five Study

Kwee Yong, MD PhD, Samantha Hinsley, MSc, BSc, Debbie Sherratt, Jessica Kendall, BSc, MSc, Sarah R Brown, PhD MSc, BSc, Louise Flanagan, PhD, Catherine Williams, Jamie Cavenagh, MD PhD, Martin Kaiser, MD, Neil K Rabin, MD, Karthik Ramasamy, MD PhD, Mamta Garg, Holger W. Auner, MD PhD, Stephen F. Hawkins, MBChB, MRCP, Ceri Bygrave, MD FRCPath, MPhil, Ruth M De Tute, BSc,MSc, Gareth Morgan, MD, Faith E. Davies, MD, Roger G. Owen
Journal: Blood
Blood (2018) 132 (Supplement 1): 306.
https://doi.org/10.1182/blood-2018-99-116624
Published: 2018
Journal Articles

Carfilzomib, Cyclophosphamide and Dexamethasone (KCD) Versus Bortezomib, Cyclophosphamide and Dexamethasone (VCD) for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): First Final Analysis of the Phase 2 Muk Five Study

Kwee Yong, PhD, Samantha Hinsley, Holger W. Auner, MD PhD, Debbie Sherratt, Ruth Mary De Tute, BSc,MSc, Sarah Brown, Louise Flanagan, Cathy Williams, Jamie Cavenagh, Martin F Kaiser, MD, Neil Rabin, Karthik Ramasamy, Mamta Garg, MD, Stephen F. Hawkins, MBChB, MRCP, Ceri Bygrave, MD FRCPath, MPhil, Gareth J. Morgan, MD PhD, Faith E. Davies, MD, Roger G Owen, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 835.
https://doi.org/10.1182/blood.V130.Suppl_1.835.835
Published: 2017